CEBPA and hepatocellular carcinoma: In a first-in-human study in patients with advanced hepatocellular cancer (NCT02716012), MTL-CEBPA displayed a good safety profile and potential anti-tumor activity when followed by treatment with tyrosine kinases inhibitors [310].